Department of Internal Medicine, Iran University of Medical Sciences, Tehran, Iran
Research Article
Aspirin Use and Risk of Pancreatic Ductal Adenocarcinoma: A Large Case-Control Study
Author(s): Zahra Momayez Sanat, Sahar Masoudi, Seidamir Pasha Tabaeian, Maryam Jameh Shorani, Majid Soruri and Akram Pourshams*
Background: Pancreatic Ductal Adeno Carcinoma (PDAC) is one of the deadliest cancers, with a fiveyear survival rate of approximately 5%. The incidence and mortality rates of PDAC are increasing and the results of medical treatments remain unsatisfactory. Some conflicting evidence suggests that aspirin intake may reduce the risk of PDAC. This study aimed to evaluate the association between regular low-dose aspirin use (80 mg aspirin tablets, 5-7 tablets/week) and the risk of PDAC.
Methods: This prospective, hospital based, case control study was performed on 470 PDAC patients (case group) and 526 controls, who were matched in terms of gender and age, in Tehran, Iran from 2011 to 2018. The participants were interviewed regarding the patterns of aspirin use. Data are expressed as mean ± SD or frequency and percentage as appropriate. Diff.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 